| Item Type | Name |
|
Concept
|
Heterocyclic Compounds, 4 or More Rings
|
|
Concept
|
Bridged Bicyclo Compounds, Heterocyclic
|
|
Academic Article
|
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
|
|
Academic Article
|
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
|
|
Academic Article
|
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
|
|
Academic Article
|
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
|
|
Academic Article
|
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
|
|
Academic Article
|
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
|
|
Academic Article
|
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
|
|
Academic Article
|
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
|
|
Academic Article
|
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
|
|
Academic Article
|
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
|
Academic Article
|
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
|
|
Academic Article
|
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
|
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
|
|
Academic Article
|
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
|
|
Academic Article
|
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
|
|
Academic Article
|
First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
|
|
Academic Article
|
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
|
|
Academic Article
|
How I manage CLL with venetoclax-based treatments.
|
|
Academic Article
|
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
|
|
Academic Article
|
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
|
|
Academic Article
|
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
|
|
Academic Article
|
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
|
|
Academic Article
|
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
|
|
Academic Article
|
Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
|
|
Academic Article
|
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
|
|
Academic Article
|
Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD.
|
|
Academic Article
|
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
|
|
Academic Article
|
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
|